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history in pack years is 39.5. Fifty two (67.5%) patients were classified as
low risk, 14 (18.2%) as intermediate risk, and 11 (14.3%) as high risk. The
mean days of hospital stay is 10.4. 72 patients (93.5%) were discharged
improved, and 5 (6.5%) patients died. Those who died had a DECAF score
>2, showing a statistically significant relationship between DECAF score
and mortality (P = .00002). A DECAF Score (>2) has 100%
sensitivity, 91.67% specificity, AUC of 0.958, PPV is 45.46 and NPV of
100.00.
Conclusion: The DECAF Score which incorporates indices routinely
available at the time of hospital admission, is an effective clinical tool that
can risk stratify and predict mortality in patients hospitalized with an exac-
erbation of COPD.
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Background and Aims: Spanish chronic obstructive pulmonary dis-
ease (COPD) guideline classifies COPD into 4 clinical phenotypes: non-
exacerbator (A), asthma-COPD overlap (B), exacerbator with emphysema
(C) and exacerbator with bronchitis (D).
Methods: A cross-sectional study of quality of life (QOL) based on
COPD phenotypes utilizing St George’s Respiratory Questionnaire
(SGRQ-c) conducted in University Malaya Medical Center from 1 June
2017 – 31 May 2018.
Results: Of 220 patients, 189 patients with post bronchodilator force
expiratory volume in 1 second (FEV1)/force vital capacity (FVC) of <0.70
were recruited. Their demographic, clinical characteristics and SGRQ-c
score are as shown in Table 1. Patients with phenotype C and D had
poorer modified medical research center (MMRC) performance status
and global initiative for COPD (GOLD) class based on FEV1. Neverthe-
less, only patients with phenotype D had significant higher total SGRQ-c
score than others. They also scored significant higher in sub-components
of COPD symptoms, activities and impacts. Patients with phenotypes B
had numerically higher SGRQ-c total and symptoms score than those
with phenotype A and C. The total and sub-components SGRQ-c score of
patients with phenotype A and C were almost similar.
Conclusion: Patients with phenotype D had poorest QOL, followed
by phenotype B. These groups of patients need additional medical
attention, in terms of pharmacology treatment, physiotherapy and
rehabilitation.
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Background and Aims: The present study was initiated to explore
the effect of Bufei Yishen granules (BY) against alveolar epithelial apopto-
sis via regulating by PERK/eIF2α signalling in chronic obstructive pulmo-
nary disease (COPD) rat model.
Methods: Rats were randomized into Control, Model, BY, and ami-
nophylline (APL) groups. COPD rats were induced by cigarette-smoke
and bacterial exposures (weeks 1–8), and were administrated with normal
saline, BY granules or aminophylline from week 9 to 16. Pulmonary func-
tion (VT, PEF) was measured every 4 weeks. Lung tissue histology and
ultrastructure, alveolar epithelial apoptosis index, PERK, eIF2α, bcl-2 and
Bad mRNA as well as protein expressions of PERK, eIF2α, p-PERK, p-
eIF2α in lung tissues were measured.
Results: VT, PEF decreased from week 8 in COPD rats (P < 0.05).
Compared with Model group, VT, PEF were higher in BY groups at week
16, while only VT was higher in APL group (P < 0.05). Markedly histologi-
cal and ultrastructural changes, including thickened respiratory mem-
brane, vacuolar lamellar corpuscle and reduced mitochondria, were found
in COPD rats and were alleviated in the treated groups, especially in BY
group. The epithelial apoptosis index significantly increased in COPD rats
(P < 0.01), and it decreased in BY and APL groups, while that in BY
group was lower than in APL group (P < 0.01). PERK, eIF2α, Bad mRNA
increased and Bcl-2 mRNA decreased in COPD rats. PERK, eIF2α and
Bad mRNA decreased in BY group (P < 0.05). PERK and Bad mRNA in
BY group was lower than that in APL group (P < 0.05). The protein
expression of PERK, eIF2α, p-PERK, p-eIF2α increased in Model group
(P < 0.01). PERK, p-PERK, p-eIF2α expression in BY group and p-eIF2α
APL group decreased compared with Model group (P < 0.05).
Conclusion: Bufei Yishen granules has the beneficial effects in
COPD and can inhibit alveolar epithelial apoptosis, the activation of
PERK/eIF2α signalling might be involved in the underlying mechanisms.
Respirology (2018) 23 (Suppl. 2), 90–334 Editorial material and organization © 2018 Asian Pacific Society of Respirology.
Copyright of individual abstracts remains with the authors
Abstracts 129
